Relationship of Levels of EPO and Hepcidin in serum with Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome
YAO Yu, ZHU Hui
Department of Hematology, Tongchuan People's Hospital, Tongchuan Shaanxi 727100
Abstract：【Objective】To investigate the correlation of serum erythropoietin (EPO) and ferromodulin (Hepcidin) levels with the prognosis of myelodysplastic syndrome (MDS) after allogeneic hemopoietic stem cell transplantation (myelodysplastic syndrome-HSCT).【Methods】A total of 175 patients with MDS treated with allo-HSCT in our hospital from January 2018 to January 2020 were selected for the study. They were divided into the survival group (n=113) and the death group (n=62) based on the 36-month follow-up results. Patients' gender, age, the International Prognostic Integration System Revision (IPSS-R), pre-HSC cell transplant complications index (HCT-CI), HLA compatibility, chromosomal karyotype, bone marrow primitive cell ratio, neutrophil count, platelet count, hemoglobin, EPO, Hepcidin were collected and compared between groups. Spearman analysis was applied to evaluate the relationship between serum EPO and Hepcidin in MDS patients. Survival analysis of MDS patients was performed using the product limit (K-M) method and the Log-rank test was compared the significance.Multivariate Logistic regression model was used to analyze the factors affecting the prognostic survival status of patients with MDS who received allo-HSCT.【Results】The proportion of IPSS-R, HCT-CI, chromosome karyotype, and bone marrow primitive cells in the survival group was compared with the death group, and the difference was statistical significant (P<0.05). In contrast to the survival group, serum EPO level was lower in the death group (P<0.05), while the level of Hepcid in was higher (P<0.05).Compared to patients with high level of EPO, those with low level of EPO had a lower survival rate (P<0.05) and a shorter survival period (P<0.05); Compared to patients with low level of Hepcidin, those with high level of Hepcidin had a lower survival rate (P<0.05) and the survival time was shorter(P<0.05).Spearman analysis showed that serum EPO and Hepcidin levels in MDS patients were negatively correlated (P<0.05)Multivariate Logistic regression analysis showed that the IPSS-R was poor to extremely poor, HCT-CI≥3, low EPO level, and high Hepcidin level were independent risk factors affecting the prognostic survival status of MDS patients (P<0.05).【Conclusion】The serum EPO and Hepcidin levels of MDS patients are closely associated with the prognostic survival of allo-HSCT, which may be used for prognostic death risk assessment.
姚玉, 朱晖. 血清EPO、Hepcidin水平与骨髓增生异常综合征异基因造血干细胞移植预后的相关性[J]. 医学临床研究, 2022, 39(3): 335-339.
YAO Yu, ZHU Hui. Relationship of Levels of EPO and Hepcidin in serum with Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome. JOURNAL OF CLINICAL RESEARCH, 2022, 39(3): 335-339.
[1] 刘子闲, 吕梦楠, 王茜茜, 等. 异基因造血干细胞移植治疗骨髓增生异常综合征的预后因素分析[J].中华血液学杂志, 2019, 40(6):484-489. [2] GATTERMANN N. Iron overload in myelodysplastic syndromes (MDS)[J].Int J Hematol,2018, 107(1):55-63. [3] SHAMMO J M, KOMROKJI R S. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy[J].Expert Rev Hematol,2018, 11(7):577-586. [4] 姜毅, 安萌萌, 龚平. 乌司他丁对脓毒症患者铁代谢及病情严重程度和预后的影响[J].中华急诊医学杂志, 2019, 28(3):361-365. [5] BALAIAN E, WOBUS M, WEIDNER H, et al. Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway[J].Haematologica,2018, 103(1):61-68. [6] 谢万祥, 黄金平. 睾酮对慢性肾功能衰竭大鼠肾性贫血的影响及其作用机制[J].安徽医药, 2018, 22(8):1454-1456. [7] 中华医学会血液学分会. 骨髓增生异常综合征诊断与治疗中国专家共识(2014年版)[J].中华血液学杂志, 2014,35(11):1042-1048. [8] 蒋煜新, 张灵, 陈子兴, 等. 影响造血干细胞移植的骨髓增生异常综合征患者生存期的因素分析[J].中国实验血液学杂志, 2020, 28(4):1283-1291. [9] PAPAGEORGIOU S G, VASILATOU D, KONTOS C K, et al. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group[J].Am J Hematol,2018, 93(7):895-901. [10] 左二冬.放疗相关性贫血患者血清Hepcidin, EPO表达特征[J].现代检验医学杂志, 2020, 35(2):43-45. [11] GURNARI C, LATAGLIATA R, BUCCISANO F, et al. Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes[J].Leuk Res,2018, 71(1):89-91. [12] 中华医学会血液学分会红细胞学组. 重组人促红细胞生成素治疗骨髓衰竭性疾病贫血专家共识[J].中华医学杂志, 2018, 98(42):3396-3400. [13] 陈吉林, 林洪丽. 慢性肾脏病患者铁缺乏及铁代谢[J].中国血液净化, 2020, 19(6):368-371. [14] 王丽, 黄连春, 李瑶芸, 等. HbHCS患者的氧化应激状态及其对Hepcidin的调节[J].中国实验血液学杂志, 2018, 26(5):1465-1470. [15] 林霞, 冯江超. 铁调素与肾性贫血相关影响因素的研究进展[J].中国血液净化, 2018, 17(5):308-312. [16] PARK S, KOSMIDER O, MALOISEL F, et al. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes[J].Haematologica,2019, 104(3):497-504.
2022, Vol. 39 
